Pfizer plans to be 'very active' in obesity market, but CEO mum on precise R&D plans
Pfizer plans to be 'very active' in obesity market, but CEO mum on precise R&D plans mbayer Wed, 05/01/2024 - 13:55
Pfizer plans to be 'very active' in obesity market, but CEO mum on precise R&D plans mbayer Wed, 05/01/2024 - 13:55
Moderna exits gene editing deal worth up to $3B biobucks, leaving Metagenomi in the spotlight aarmstrong Wed, 05/01/2024 - 13:53
Astellas hitches a ride in Poseida's convertible for $50M cell therapy collaboration aarmstrong Wed, 05/01/2024 - 12:15
Bob Nelsen on ARCH-led megarounds: ‘We want the IPO book in the seed round’ mbayer Wed, 05/01/2024 - 10:19
Pepper Bio spices up pipeline with $135M deal for G1 Therapeutics’ CDK4/6 inhibitor jwaldron Wed, 05/01/2024 - 09:33
How Lilly is using its Mounjaro millions to position as biotechs’ ‘partner of choice’ jwaldron Wed, 05/01/2024 - 07:21
Jacobio's KRAS data tee up safety-focused pitch for lung cancer market ntaylor Wed, 05/01/2024 - 07:02